Volume 24, Issue 2 pp. 268-273
ORIGINAL ARTICLE

Risk factors for cancer-associated myositis: A large-scale multicenter cohort study

Yimin Li

Yimin Li

Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China

Search for more papers by this author
Xiaohui Jia

Xiaohui Jia

Department of Rheumatology, The First Hospital of Hebei Medical University, Shijiazhuang, China

Search for more papers by this author
Xiaolin Sun

Xiaolin Sun

Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China

Search for more papers by this author
Lianjie Shi

Lianjie Shi

Department of Rheumatology, Peking University International Hospital, Beijing, China

Search for more papers by this author
Fuan Lin

Fuan Lin

Department of Rheumatology, People’s Hospital of Jianyang City, Jianyang, China

Search for more papers by this author
Yuzhou Gan

Yuzhou Gan

Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China

Search for more papers by this author
Xuewu Zhang

Xuewu Zhang

Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China

Search for more papers by this author
Xiaojuan Gao

Xiaojuan Gao

Department of Rheumatology, Ningde Hospital, Affiliated Hospital of Fujian Medical University, Ningde, China

Search for more papers by this author
Miao Miao

Miao Miao

Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China

Search for more papers by this author
Daojun Hong

Daojun Hong

Department of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, China

Search for more papers by this author
Yuhui Li

Corresponding Author

Yuhui Li

Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China

Correspondence

Yuhui Li and Jing He, Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China.

Emails: [email protected]; [email protected]

Search for more papers by this author
Jing He

Corresponding Author

Jing He

Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China

Correspondence

Yuhui Li and Jing He, Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China.

Emails: [email protected]; [email protected]

Search for more papers by this author
First published: 26 December 2020
Citations: 19
Yimin Li and Xiaohui Jia are equal contributions and are designated as co-first authors. Yuhui Li and Jing He are equal contributions as corresponding authors directing this study.
"/>

Abstract

Aim

The aim of this study was to identify the risk factors and prognosis of patients with cancer-associated myositis (CAM).

Method

Four hundred and eighty-seven patients with dermatomyositis (DM), clinical amyopathic dermatomyositis (CADM) and polymyositis (PM) from 3 clinical centers were enrolled retrospectively in this study. Clinical and laboratory data of CAM and non-CAM patients were compared. Logistic regression analysis was used to identify risk factors of CAM.

Results

Out of the 487 patients with DM/CADM/PM, 7.0% (34/487) of patients were classified as CAM. Older age (53.91 ± 13.32 vs. 48.76 ± 14.34 years), heliotrope rash (61.8% vs. 41.9%), shawl sign (41.2% vs. 22.1%), V sign (58.8% vs. 38.6%) were observed significantly more commonly in patients with CAM than those without CAM (all P < .05). Fever (17.7% vs. 37.8%), arthralgia/arthritis (23.5% vs. 45.7%), interstitial lung disease (ILD, 38.2% vs 68.9%) were significantly less common in the CAM group than the non-CAM group. Age at onset (odds ratio [OR] 1.036, 95% CI 1.001-1.072, P = .042), shawl sign (OR 2.748, 95% CI 1.107-6.822, P = .029), anti-transition initiation factor (TIF)-1γ antibody (OR 4.012, 95% CI 1.268-12.687, P = .018) were identified as the initial risk factors for the onset of CAM, and ILD was identified as a protective factor for CAM (OR 0.292, 95% CI 0.115-0.739, P = .009). All-cause mortality was significantly higher in CAM patients compared with non-CAM patients (P = .001).

Conclusion

The mortality of patients with CAM was higher than DM/CADM/PM patients without cancer. Malignancy should be screened in DM/CADM/PM patients especially with risk factors, including older age, shawl sign, anti-TIF-1γ antibody, and lack of ILD.

CONFLICT OF INTEREST

The authors have declared no conflicts of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.